UC Berkeley
FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies
In a draft guidance, the agency outlined how the well-understood and reproducible components of genetic medicines could qualify as platform technologies.
The center, led by Jennifer Doudna and Fyodor Urnov and funded by Danaher, is also developing CRISPR therapies for two rare immune disorders.
Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women
Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.